These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 19691668)

  • 1. Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease.
    Vilar Gomez E; Rodriguez De Miranda A; Gra Oramas B; Arus Soler E; Llanio Navarro R; Calzadilla Bertot L; Yasells Garcia A; Del Rosario Abreu Vazquez M
    Aliment Pharmacol Ther; 2009 Nov; 30(10):999-1009. PubMed ID: 19691668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study.
    Nobili V; Manco M; Ciampalini P; Alisi A; Devito R; Bugianesi E; Marcellini M; Marchesini G
    Clin Ther; 2008 Jun; 30(6):1168-76. PubMed ID: 18640473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.
    Bugianesi E; Gentilcore E; Manini R; Natale S; Vanni E; Villanova N; David E; Rizzetto M; Marchesini G
    Am J Gastroenterol; 2005 May; 100(5):1082-90. PubMed ID: 15842582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial.
    Harrison SA; Fecht W; Brunt EM; Neuschwander-Tetri BA
    Hepatology; 2009 Jan; 49(1):80-6. PubMed ID: 19053049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial.
    Nobili V; Manco M; Devito R; Di Ciommo V; Comparcola D; Sartorelli MR; Piemonte F; Marcellini M; Angulo P
    Hepatology; 2008 Jul; 48(1):119-28. PubMed ID: 18537181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of vitamin E on aminotransferase levels and insulin resistance in children with non-alcoholic fatty liver disease.
    Nobili V; Manco M; Devito R; Ciampalini P; Piemonte F; Marcellini M
    Aliment Pharmacol Ther; 2006 Dec; 24(11-12):1553-61. PubMed ID: 17206944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of a hypocaloric diet in transaminases in nonalcoholic fatty liver disease and obese patients, relation with insulin resistance.
    de Luis DA; Aller R; Izaola O; Sagrado MG; Conde R; Gonzalez JM
    Diabetes Res Clin Pract; 2008 Jan; 79(1):74-8. PubMed ID: 17766001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease.
    Zelber-Sagi S; Kessler A; Brazowsky E; Webb M; Lurie Y; Santo M; Leshno M; Blendis L; Halpern Z; Oren R
    Clin Gastroenterol Hepatol; 2006 May; 4(5):639-44. PubMed ID: 16630771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial.
    Ratziu V; Giral P; Jacqueminet S; Charlotte F; Hartemann-Heurtier A; Serfaty L; Podevin P; Lacorte JM; Bernhardt C; Bruckert E; Grimaldi A; Poynard T;
    Gastroenterology; 2008 Jul; 135(1):100-10. PubMed ID: 18503774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement.
    Dixon JB; Bhathal PS; O'Brien PE
    Obes Surg; 2006 Oct; 16(10):1278-86. PubMed ID: 17059735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease.
    Targher G; Bertolini L; Padovani R; Rodella S; Zoppini G; Zenari L; Cigolini M; Falezza G; Arcaro G
    Diabetes Care; 2006 Jun; 29(6):1325-30. PubMed ID: 16732016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease.
    Hossain N; Afendy A; Stepanova M; Nader F; Srishord M; Rafiq N; Goodman Z; Younossi Z
    Clin Gastroenterol Hepatol; 2009 Nov; 7(11):1224-9, 1229.e1-2. PubMed ID: 19559819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease.
    Targher G; Bertolini L; Rodella S; Zoppini G; Scala L; Zenari L; Falezza G
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):679-83. PubMed ID: 16712671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis.
    Bugianesi E; Marchesini G; Gentilcore E; Cua IH; Vanni E; Rizzetto M; George J
    Hepatology; 2006 Dec; 44(6):1648-55. PubMed ID: 17133473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels.
    Wong VW; Wong GL; Tsang SW; Hui AY; Chan AW; Choi PC; Chim AM; Chu S; Chan FK; Sung JJ; Chan HL
    Aliment Pharmacol Ther; 2009 Feb; 29(4):387-96. PubMed ID: 19035982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD.
    Kang H; Greenson JK; Omo JT; Chao C; Peterman D; Anderson L; Foess-Wood L; Sherbondy MA; Conjeevaram HS
    Am J Gastroenterol; 2006 Oct; 101(10):2247-53. PubMed ID: 17032189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum alanine aminotransferase levels decrease further with carbohydrate than fat restriction in insulin-resistant adults.
    Ryan MC; Abbasi F; Lamendola C; Carter S; McLaughlin TL
    Diabetes Care; 2007 May; 30(5):1075-80. PubMed ID: 17351275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term prognosis of nonalcoholic fatty liver disease: is pharmacological therapy actually necessary?
    Cinar K; Coban S; Idilman R; Tuzun A; Sarioglu M; Bektas M; Erden E; Bozkaya H; Ozden A
    J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):169-73. PubMed ID: 16706829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intragastric balloon significantly improves nonalcoholic fatty liver disease activity score in obese patients with nonalcoholic steatohepatitis: a pilot study.
    Lee YM; Low HC; Lim LG; Dan YY; Aung MO; Cheng CL; Wee A; Lim SG; Ho KY
    Gastrointest Endosc; 2012 Oct; 76(4):756-60. PubMed ID: 22840293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years.
    Furuya CK; de Oliveira CP; de Mello ES; Faintuch J; Raskovski A; Matsuda M; Vezozzo DC; Halpern A; Garrido AB; Alves VA; Carrilho FJ
    J Gastroenterol Hepatol; 2007 Apr; 22(4):510-4. PubMed ID: 17376042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.